Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Drugs in Development
Details:
Ocrevus Zunovo (ocrelizumab-hyaluronidase) is a humanised mAb-enzyme designed to target CD20-positive B cells, approved for the treatment of multiple sclerosis.
Lead Product(s): Ocrelizumab,Hyaluronidase
Therapeutic Area: Neurology Brand Name: Ocrevus Zunovo
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2024
Lead Product(s) : Ocrelizumab,Hyaluronidase
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Ocrevus Zunovo as First Twice-a-Year Subcutaneous Injection for MS
Details : Ocrevus Zunovo (ocrelizumab-hyaluronidase) is a humanised mAb-enzyme designed to target CD20-positive B cells, approved for the treatment of multiple sclerosis.
Brand Name : Ocrevus Zunovo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 13, 2024
Details:
OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, approved as a subcutaneous injection, for the treatment of multiple sclerosis.
Lead Product(s): Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area: Neurology Brand Name: Ocrevus
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2024
Lead Product(s) : Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Roche’s OCREVUS Subcutaneous Admin Approved as Twice-a-Year Injection for MS
Details : OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, approved as a subcutaneous injection, for the treatment of multiple sclerosis.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 25, 2024
Details:
Ocrevus (ocrelizumab) is a twice-yearly subcutaneous injection designed to target CD20-positive B cells for treating progressive and relapsing multiple sclerosis.
Lead Product(s): Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area: Neurology Brand Name: Ocrevus
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Lead Product(s) : Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Roche’s Subcutaneous OCREVUS Shows Strong One-Year Results in MS Patients
Details : Ocrevus (ocrelizumab) is a twice-yearly subcutaneous injection designed to target CD20-positive B cells for treating progressive and relapsing multiple sclerosis.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 17, 2024
Details:
OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, which is being investigated as a a 10-minute subcutaneous injection, for the treatment of multiple sclerosis.
Lead Product(s): Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area: Neurology Brand Name: Ocrevus
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Lead Product(s) : Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, which is being investigated as a a 10-minute subcutaneous injection, for the treatment of multiple sclerosis.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 13, 2023
Details:
OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage.
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Brand Name: Ocrevus
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 26, 2022
Details:
OCREVUS (ocrelizumab) data will show significant benefit on slowing disease activity and progression in patients with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS).
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Brand Name: Ocrevus
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OCREVUS (ocrelizumab) data will show significant benefit on slowing disease activity and progression in patients with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS).
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 19, 2022
Details:
Ocrevus (Ocrelizumab) data will show significant benefit on slowing disease activity and progression in patients with treatment-naïve early-stage relapsing-remitting multiple sclerosis (RRMS).
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Brand Name: Ocrevus
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ocrevus (Ocrelizumab) data will show significant benefit on slowing disease activity and progression in patients with treatment-naïve early-stage relapsing-remitting multiple sclerosis (RRMS).
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 18, 2022
Details:
Analysis demonstrated positive effects of OCREVUS on cognition, with 70% of patients having improved cognition, as measured with SDMT. Clinically meaningful improvement was observed in 34% of patients treated with OCREVUS and worsening in 30% of patients treated with OCREVUS.
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Brand Name: Ocrevus
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
New Data for Roche’s Ocrevus (Ocrelizumab) Show Benefit in Disability Progression and Cognitive ...
Details : Analysis demonstrated positive effects of OCREVUS on cognition, with 70% of patients having improved cognition, as measured with SDMT. Clinically meaningful improvement was observed in 34% of patients treated with OCREVUS and worsening in 30% of patients...
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 04, 2022
Details:
OCREVUS (ocrelizumab), a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage.
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Brand Name: Ocrevus
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Genentech
Deal Size : Not Applicable
Deal Type : Not Applicable
Roche to Present Data Across Broad and Impactful Neuroscience Portfolio at 2022 AAN Annual Meeting
Details : OCREVUS (ocrelizumab), a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 25, 2022
Details:
OCREVUS resulted in a 35% reduction in the risk of patients with RMS needing a walking aid over seven and a half years compared with patients who switched from interferon beta-1a to OCREVUS after the 96-week double-blind period.
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Brand Name: Ocrevus
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
Lead Product(s) : Ocrelizumab
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Data up to 8-years for Roche’s OCREVUS (Ocrelizumab) Show Early and Ongoing Treatment Significan...
Details : OCREVUS resulted in a 35% reduction in the risk of patients with RMS needing a walking aid over seven and a half years compared with patients who switched from interferon beta-1a to OCREVUS after the 96-week double-blind period.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finished Drug Prices
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Annual Reports
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 3,819
2018 Revenue in Millions : 2,424
Growth (%) : 58
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 845
2019 Revenue in Millions : 688
Growth (%) : 23
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 4,820
2019 Revenue in Millions : 4,131
Growth (%) : 17
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 5,440
2020 Revenue in Millions : 4,586
Growth (%) : 17
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 6,598
2021 Revenue in Millions : 5,440
Growth (%) : 21
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 7,403
2022 Revenue in Millions : 6,598
Growth (%) : 6
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 688
2018 Revenue in Millions : 478
Growth (%) : 44
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 921
2016 Revenue in Millions : 0
Growth (%) : New Launch
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 2,377
2017 Revenue in Millions : 878
Growth (%) : 171%
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
